Physiologically based pharmacokinetic models for predicting lamotrigine exposure and dose optimization in pediatric patients receiving combination therapy with carbamazepine or valproic acid

• Published in: Pharmacotherapy 2024-09, Vol.44 (9), p.711-721
• Main Authors: Liu, Zhiwei, Shao, Wenxin, Wang, Xingwen, Geng, Kuo, Wang, Wenhui, Li, Yiming, Chen, Youjun, Xie, Haitang
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Anticonvulsants - administration & dosage; Anticonvulsants - pharmacokinetics; Antiepileptic agents; Carbamazepine; Carbamazepine - administration & dosage; Carbamazepine - pharmacokinetics; Child; Child, Preschool; Children; Combination therapy; Dose-Response Relationship, Drug; Drug dosages; Drug interaction; Drug Interactions; Drug Therapy, Combination; Epilepsy; Epilepsy - drug therapy; Female; Humans; Lamotrigine; Lamotrigine - administration & dosage; Lamotrigine - pharmacokinetics; Male; Models, Biological; pediatric; Pediatrics; Pharmacokinetics; physiologically based pharmacokinetic model; Triazines - administration & dosage; Triazines - pharmacokinetics; Valproic acid; Valproic Acid - administration & dosage; Valproic Acid - pharmacokinetics; Young Adult
• ISSN: 0277-0008; 1875-9114; 1875-9114
• DOI: 10.1002/phar.4603

Introduction Lamotrigine (LTG) is an antiepileptic drug that has been used in pediatric epilepsy as a combination therapy or monotherapy after stabilization in recent years. However, there are significant drug–drug interactions (DDI) between LTG and combined drugs such as carbamazepine (CBZ) and valproic acid (VPA). It is particularly important to consider the risk of DDI in combination therapy for intractable epilepsy in pediatric patients. Therefore, it is necessary to adjust the dosage of LTG accordingly. The aim of this study was to establish and validate a pediatric physiologically based pharmacokinetic (PBPK) model for predicting LTG exposure. The model is designed to explore the potential for quantifying pharmacokinetic (PK) DDI of LTG when administered concurrently with CBZ or VPA in pediatric patients. Method Adult and pediatric PBPK models for LTG and VPA were developed using PK‐Sim® software in combination with physiological information and drug‐specific parameters, and a DDI model was developed in combination with the published CBZ model. The models were validated against available PK data. Results Predictive and observational results in adults, children, and the DDI model were in good agreement. The recommended doses of LTG for preschool children (2–6 years) and school‐aged children (6–12 years) in the absence of drug interactions were 1.47 and 1.2 times higher than those for adults, respectively; 3.1 and 2.6 times higher than those for adults in combination with CBZ; and 0.67 and 0.57 times lower than those for adults in combination with VPA. In addition, plasma exposures in adolescents (12–18 years) were similar to those in adults at the same doses. Conclusion We have successfully developed PBPK models and DDI models for LTG in adults and children, which provide a reference for rational drug use in the pediatric population.